Premium
FDA approves chewable methylphenidate
Publication year - 2016
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30098
Subject(s) - methylphenidate , food and drug administration , attention deficit hyperactivity disorder , medicine , psychiatry , drug , pharmacology
The U.S. Food and Drug Administration on December 4 approved QuilliChew ER tablets, which Pfizer officials are calling the first and only long‐acting chewable methylphenidate treatment for attention‐deficit hyperactivity disorder (ADHD) in patients ages 6 years old and above.